KYORIN Pharmaceutical (4569) · InitiativeAdvanced
Development and Commercialization Agreement with HIF for a Chronic Cough Therapeutic App
First written in FY2025. 3 of 4 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-07-30.
4entries
2years
1from disclosures
How it moved
Same theme, other companies
Development and commercialization partnership with ハイフ for a chronic cough therapeutic appA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-07-30AdvancedEarnings presentation
「KRP-DC125 Chronic cough Confirmatory clinical trial (June 2026)*」
KRP-DC125 progressed from preparations to conduct a confirmatory trial to the confirmatory trial stage in June 2026. The original thread remains unchanged. - FY2026AdvancedAnnual report
「Development of the KRP-DC125 app for the treatment of chronic cough is progressing steadily, including preparations for conducting a confirmatory trial.」
KRP-DC125 progressed from a description of development progress to the preparation stage for conducting a confirmatory trial. - FY2026-H1AdvancedAnnual report
「Development of the app for the treatment of chronic cough, KRP-DC125, is progressing steadily,」
The Company described progress in the development of the KRP-DC125 app for the treatment of chronic cough under its development and commercialization agreement with ハイフ社. - FY2025First statedAnnual report
「In February of that year, we announced that development of a therapeutic app for chronic cough was under way in Japan under a development and commercialization agreement with HIF.」
The Company announced that it was developing a therapeutic app for chronic cough in Japan under a development and commercialization agreement with HIF.